C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.
1. A compound of the formula:
wherein:
n is 0-3;
Ar is heteroarenediyl (C≦8) or a substituted version thereof; and
Y is:
hydrogen, hydroxy, halo, amino, or cyano or —NCO; or
alkyl (C≦8) , alkenyl (C≦8) , alkynyl (C≦8) , aryl (C≦12) , aralkyl (C≦12) , heteroaryl (C≦8) , heterocycloalkyl (C≦12) , acyl (C≦12) , alkoxy (C≦8) , aryloxy (C≦12) , acyloxy (C≦8) , alkylamino (C≦8) , dialkylamino (C≦8) , arylamino (C≦8) , aralkylamino (C≦8) , alkylthio (C≦8) , acylthio (C≦8) , alkylsulfonylamino (C≦8) , or substituted versions of any of these groups;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein Y is —H.
3. The compound of claim 1 , wherein Y is alkyl (C≦4) .
4. The compound of claim 3 , wherein Y is methyl, n-propyl, isopropyl or cyclopropyl.
5. The compound of claim 1 , wherein Y is substituted alkyl (C≦4) .
6. The compound of claim 5 , wherein Y is methoxymethyl.
7. The compound of claim 1 , wherein Ar is
8. The compound of claim 1 , wherein n=0.
9. The compound of claim 1 , wherein n=1.
10. The compound of claim 1 , further defined as:
or a pharmaceutically acceptable salt thereof.
11. A pharmaceutical composition comprising:
a) the compound of claim 1 ; and
b) an excipient.